Tau PET in Imaging and Cognition: Healthy Adults From 55-90

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yaakov Stern
• Collaborator: National Institute on Aging (NIA)

Criteria

Inclusion Criteria:

• Aged 55-90

• Previously received an amyloid PET scan

• Residing near Columbia University Medical Center

• Must be willing and able to participate

Exclusion Criteria:

• Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour)

• Pregnancy

• Lactating Women

• Current, past, or anticipated exposure to radiation

• Significant active physical illness